Zim (ZIMCF) Cash-to-Debt: 19.27 (As of Sep. 2021)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Zim Cash-to-Debt?

Zim ZIMCF Cash-to-Debt is 19.27 as of Sep. 2021.

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Zim's cash to debt ratio for the quarter that ended in Sep. 2021 was 19.27.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Zim could pay off its debt using the cash in hand for the quarter that ended in Sep. 2021.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Zim's Cash-to-Debt or its related term are showing as below:

ZIMCF's Cash-to-Debt is not ranked *
in the Biotechnology industry.
Industry Median: 7.17
* Ranked among companies with meaningful Cash-to-Debt only.

Zim  (OTCPK:ZIMCF) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Zim Cash-to-Debt Related Terms

Zim Cash-to-Debt Historical Data

* Premium members only.

The historical data trend for Zim's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Zim Cash-to-Debt Chart

Zim Annual Data
Trend Mar12 Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only No Debt No Debt No Debt 221.70 13.12

Zim Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Jun21 Sep21
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.59 14.07 No Debt 16.88 19.27

ZIMCF vs MAPT, FSSN, TGHI: Cash-to-Debt Comparison

For the Biotechnology subindustry, Zim's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zim Cash-to-Debt vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zim's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Zim's Cash-to-Debt falls into.


Zim Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Zim's Cash to Debt Ratio for the fiscal year that ended in Mar. 2021 is calculated as:

Zim had no debt (1).

Zim's Cash to Debt Ratio for the quarter that ended in Sep. 2021 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=0.185549 / (0.009627 + 0)
=19.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash-to-Debt →
What does a Cash-to-Debt of 19.27 mean?
Zim (ZIMCF) has a Cash-to-Debt of 19.27 as of Sep. 2021.
Is Zim's Cash-to-Debt too high?
Zim's current Cash-to-Debt is 19.27. The Biotechnology industry median Cash-to-Debt is 7.17. Zim's value of 19.27 is 168.8% above this industry median.
How does Zim's Cash-to-Debt compare to MAPT and FSSN?
Zim's Cash-to-Debt of 19.27 can be compared against companies in the Biotechnology industry. The industry median Cash-to-Debt is 7.17. Zim's value of 19.27 is 168.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 7.17, based on 1,395 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zim's current Cash-to-Debt of 19.27 is 168.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 7.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zim's current Cash-to-Debt is 19.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zim stock overvalued right now?
Zim (ZIMCF) has a current Cash-to-Debt of 19.27. The current Cash-to-Debt is 19.27 and 168.8% above the Biotechnology industry median of 7.17. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Zim (ZIMCF), the current Cash-to-Debt is 19.27 as of Sep. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zim Business Description

Address 20 Colonade Road, Suite 200, Ottawa, ON, CAN, K2E 7M2
Zim Corp has sold its operations and is currently focused on biomedical research. The company focused all of its resources on developing intellectual property and advancing research and development in the areas of new synthetic drugs and immunotherapies. It generates geographic revenue from Canada.